Skip to content
Evoq Remedies logo

Evoq Remedies

543500 BSE
₹1.54

Close ·

View as Markdown
MCP
Close 4 Nov 2026 ₹1.54 −2.93 −65.5% 1Y
Start ₹4.47

Key Fundamentals

SMECommercial ServicesServices

Price-based figures at the close · TTM

ROCE
−0.56%
Debt to Equity
0.00
EPS (TTM)
—
Book Value
₹17.79
Market Cap
—
P/E (TTM)
—
P/B
0.09
ROE
−0.54%
Dividend Yield
0.00%
EBITDA
−₹1.45 Cr
52W High
₹4.70
52W Low
₹1.35

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

48 Average

Data confidence 84/100

Category scores

Quality
52
Average
Returns, margins, earnings quality 22% weight
Valuation
56
Good
Cheap vs sector & own history 24% weight
Growth
98
Strong
Sales & profit trajectory 9% weight
Financial Health
63
Good
Solvency, leverage, coverage 9% weight
Momentum
5
Poor
Trend strength, vol-adjusted 12% weight
Ownership
34
Poor
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is almost debt free.
  • Stock is trading at 0.11 times its book value
  • Debtor days have improved from 160 to 55.1 days.

Weaknesses

5
  • Company has low interest coverage ratio.
  • Promoter holding has decreased over last quarter: -11.2%
  • Promoter holding is low: 0.02%
  • Company has a low return on equity of 0.29% over last 3 years.
  • Contingent liabilities of Rs.6.55 Cr.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1234
OscillatorsBullish234
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
41.52
Neutral
MACD (12,26,9)
0.00
Bearish
SMA (50)
1.62
Bearish
SMA (200)
2.53
Bearish

As of

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.

Revenue

Revenue growth by window
5Y+20.55%
3Y+7.75%
1Y+116.92%

Net profit

Net profit growth by window
5YTurned to loss
3YTurned to loss
1YTurned to loss

Operating cash flow

Operating cash flow growth by window
5YTurned negative
3YOutflow narrowed by ₹4.07 Cr
1YOutflow narrowed by ₹14.34 Cr

Operating margin· change in pp

Operating margin growth by window
5Y−15.16 pp
3Y+12.61 pp
1Y+13.28 pp

Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.

Revenue by year

Revenue by year, ₹ crore
Mar 2019₹3.25 Cr
Mar 2020₹9.07 Cr
Mar 2021₹10.02 Cr
Mar 2022₹16.78 Cr
Mar 2023₹20.39 Cr
Mar 2024₹4.05 Cr
Mar 2025₹11.76 Cr
Mar 2026₹25.51 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2019₹0.01 Cr
Mar 2020₹0.00 Cr
Mar 2021₹0.72 Cr
Mar 2022₹1.09 Cr
Mar 2023₹1.62 Cr
Mar 2024₹0.45 Cr
Mar 2025₹0.09 Cr
Mar 2026−₹0.24 Cr

Half-yearly Results

₹ Cr
543500 half-yearly results, ₹ crore
Particulars Mar 2021Sep 2021Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026
Sales
2.76
4.93
11.85
15.79
4.6
3.9
0.15
0
11.76
25.51
0
Expenses
1.71
4.2
11.12
15.48
8.64
3.83
1.87
1.63
12.36
26.46
0.5
Operating Profit
1.05
0.73
0.73
0.31
−4.04
0.07
−1.72
−1.63
−0.6
−0.95
−0.5
OPM %
38.04%
14.81%
6.16%
1.96%
−87.83%
1.79%
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
—
−5.1%
−3.72%
—
Other Income
0
0
0
0
6.02
0
2.26
0.01
2.4
1.06
0.19
Interest
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0.04
0.03
0.02
PBT
1.05
0.73
0.73
0.31
1.98
0.07
0.54
−1.62
1.76
0.08
−0.33
Tax %
22.86%
0%
50.68%
0%
33.84%
28.57%
29.63%
0%
2.27%
25%
−12.12%
Net Profit
0.81
0.73
0.36
0.31
1.31
0.05
0.38
−1.62
1.71
0.05
−0.29
EPS (₹)
11.57
10.43
0.26
0.23
0.96
0.04
0.28
−0.65
0.69
0.02
−0.12

Profit & Loss

₹ Cr
543500 profit and loss, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
3.25
9.07
10.02
16.78
20.39
4.05
11.76
25.51
Expenses
3.23
9.07
9.07
15.32
24.12
5.69
13.99
26.96
Operating Profit
0.02
0
0.95
1.46
−3.73
−1.64
−2.23
−1.45
OPM %
0.62%
0%
9.48%
8.7%
−18.29%
−40.49%
−18.96%
−5.68%
Other Income
0
0
0
0
6.02
2.26
2.41
1.25
Interest
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0.01
0.05
0.05
PBT
0.02
0
0.95
1.46
2.29
0.61
0.13
−0.25
Tax %
0%
—
25.26%
25.34%
29.26%
26.23%
30.77%
−4%
Net Profit
0.01
0
0.72
1.09
1.62
0.45
0.09
−0.24
EPS (₹)
0.14
0
10.29
0.8
1.19
0.33
0.04
−0.1
Div. Payout %
0%
—
0%
0%
0%
0%
0%
0%

Balance Sheet

₹ Cr
543500 balance sheet, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.01
0.01
0.01
13.6
13.6
13.6
24.9
24.9
Reserves
0.01
0.01
0.73
9.57
11.19
11.64
19.64
19.4
Borrowings
0
0.01
0
8.16
9.58
4.24
0
0.07
Other Liabilities
2.12
5.62
7.3
2
0.53
7.39
5.47
7.57
Total Liabilities
2.14
5.65
8.04
33.33
34.9
36.87
50.01
51.94
Fixed Assets
0
0
0
0
0.01
0.01
0.22
0.17
CWIP
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
Other Assets
2.14
5.65
8.04
33.33
34.89
36.86
49.79
51.77
Total Assets
2.14
5.65
8.04
33.33
34.9
36.87
50.01
51.94

Cash Flow

₹ Cr
543500 cash flow, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0.01
−0.02
0.03
−26.43
−4.35
5.32
−14.62
−0.28
Investing
0
0
0
0
−0.01
−0.01
−0.26
0
Financing
0
0
0
29.49
1.42
−5.34
14.97
0.07
Net Cash Flow
0.01
−0.02
0.03
3.06
−2.94
−0.03
0.09
−0.21
Free Cash Flow
0.01
−0.02
0.03
−26.43
−4.36
5.31
−14.88
−0.28
CFO/EBITDA
50
—
3
−1,785
99
−334
654
19

Ratios

543500 financial ratios, annual
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
138
190
249
553
308
157
268
55.09
Inventory Days
3.39
2.42
6.97
20.66
38.33
732
61.9
23.92
Days Payable
240
227
315
32.05
—
767
97.59
10.89
Cash Conversion Cycle
−98.04
−34.3
−59.11
541
—
122
232
68.12
Working Capital Days
1.12
1.21
26.23
437
441
2,263
1,369
631
ROCE %
—
0%
246.75%
9.11%
6.97%
1.91%
0.35%
−0.56%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Evoq Remedies insights

51 extracted metrics across FY19–FY26.

Shareholding Pattern

As of Mar 2026

  • Public 94.57%
  • Others 5.41%
  • Promoters 0.02%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Evoq Remedies

What does Evoq Remedies Ltd do?
Incorporated in 2010, EVOQ Remedies Ltd is in the pharmaceutical business.
Where is Evoq Remedies Ltd (EVOQ) listed?
Evoq Remedies Ltd trades under code 543500 on the BSE.
Which sector does Evoq Remedies Ltd belong to?
Evoq Remedies Ltd is classified under the Commercial Services sector, in the Trading & Distributors industry.
What is the 52-week high and low of Evoq Remedies Ltd?
Over the last 52 weeks Evoq Remedies Ltd has traded between ₹1.35 and ₹4.7 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Evoq Remedies Ltd?
Evoq Remedies Ltd reported a return on equity of -0.54%. Its debt-to-equity ratio is 0.00.

Company Information

Incorporated in 2010, EVOQ Remedies Ltd is in the pharmaceutical business.

Website evoqremedies.com
Listed 30 Mar 2022
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/543500.md for Evoq Remedies Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Commercial Services stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month